EXP THER MED:异丙酚、咪达唑仑和右美托咪啶对ICU脓毒症患者及动脉血气的影响

2020-01-28 anesthG “罂粟花”微信号

观察异丙酚、咪达唑仑和右美托咪啶对重症监护病房(ICU)脓毒症患者及动脉血气(ABG)的影响。

背景与目的

观察异丙酚、咪达唑仑和右美托咪啶对重症监护病房(ICU)脓毒症患者及动脉血气(ABG)的影响。

方  法

选择上海交通大学仁济医院2015年5月至2019年1月收治的ICU脓毒症患者429例作为研究对象进行前瞻性分析。所有患者均接受抗感染治疗、纠正休克、改善微循环等基础治疗。将152例使用异丙酚镇静组列为A组,146例使用咪达唑仑镇静组为B组,131例使用右美托咪定镇静组为C组。比较三组患者治疗前后舒张压(DBP)、收缩压(SBP)、心率(HR)、动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)、心肌肌钙蛋白T (cTnT)、肌酸激酶(CK-MB)的变化。APACHEⅡ评分被用来评估镇静效果。记录患者苏醒时间、ICU住院时间及不良反应。

结 果

A、B、C组治疗前HR、收缩压、舒张压、PaO2、PaCO2、cTnT、CK MB、APACHE评分及治疗后收缩压、舒张压、cTnT、HR比较,差异无统计学意义(P>0.050)。治疗后A、B两组CK-MB、APACHE评分无显着性差异(P>0.050)。A组苏醒时间明显长于B、C组(P<0.001)

结 论

咪达唑仑、右美托咪啶用于ICU脓毒症患者的镇静治疗是安全有效的,但右旋美托咪啶对血压和心功能的保护作用最好,值得临床使用。

原始出处:

JIA DING, YUWEN CHEN, and YUAN GAO.Effect of propofol, midazolam and dexmedetomidine on ICU patients with sepsis and on arterial blood gas.EXPERIMENTAL AND THERAPEUTIC MEDICINE 18: 4340-4346, 2019.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1944145, encodeId=a6ed194414515, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri Jun 05 03:26:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720575, encodeId=24471e2057557, content=<a href='/topic/show?id=2b3939e938a' target=_blank style='color:#2F92EE;'>#咪达唑仑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39793, encryptionId=2b3939e938a, topicName=咪达唑仑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f92f32859800, createdName=zhanfl, createdTime=Mon Dec 14 21:26:00 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709014, encodeId=6f731e0901455, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Mon Apr 20 08:26:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378694, encodeId=96263e86949b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:18:12 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468848, encodeId=c6a41468848cf, content=<a href='/topic/show?id=5e0b49e1106' target=_blank style='color:#2F92EE;'>#异丙酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49711, encryptionId=5e0b49e1106, topicName=异丙酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18a56942427, createdName=lq0303, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516380, encodeId=c5cd1516380f4, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610205, encodeId=b7f1161020574, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378603, encodeId=25c33e860303, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Tue Jan 28 22:50:25 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1944145, encodeId=a6ed194414515, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri Jun 05 03:26:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720575, encodeId=24471e2057557, content=<a href='/topic/show?id=2b3939e938a' target=_blank style='color:#2F92EE;'>#咪达唑仑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39793, encryptionId=2b3939e938a, topicName=咪达唑仑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f92f32859800, createdName=zhanfl, createdTime=Mon Dec 14 21:26:00 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709014, encodeId=6f731e0901455, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Mon Apr 20 08:26:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378694, encodeId=96263e86949b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:18:12 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468848, encodeId=c6a41468848cf, content=<a href='/topic/show?id=5e0b49e1106' target=_blank style='color:#2F92EE;'>#异丙酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49711, encryptionId=5e0b49e1106, topicName=异丙酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18a56942427, createdName=lq0303, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516380, encodeId=c5cd1516380f4, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610205, encodeId=b7f1161020574, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378603, encodeId=25c33e860303, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Tue Jan 28 22:50:25 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1944145, encodeId=a6ed194414515, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri Jun 05 03:26:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720575, encodeId=24471e2057557, content=<a href='/topic/show?id=2b3939e938a' target=_blank style='color:#2F92EE;'>#咪达唑仑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39793, encryptionId=2b3939e938a, topicName=咪达唑仑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f92f32859800, createdName=zhanfl, createdTime=Mon Dec 14 21:26:00 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709014, encodeId=6f731e0901455, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Mon Apr 20 08:26:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378694, encodeId=96263e86949b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:18:12 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468848, encodeId=c6a41468848cf, content=<a href='/topic/show?id=5e0b49e1106' target=_blank style='color:#2F92EE;'>#异丙酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49711, encryptionId=5e0b49e1106, topicName=异丙酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18a56942427, createdName=lq0303, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516380, encodeId=c5cd1516380f4, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610205, encodeId=b7f1161020574, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378603, encodeId=25c33e860303, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Tue Jan 28 22:50:25 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1944145, encodeId=a6ed194414515, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri Jun 05 03:26:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720575, encodeId=24471e2057557, content=<a href='/topic/show?id=2b3939e938a' target=_blank style='color:#2F92EE;'>#咪达唑仑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39793, encryptionId=2b3939e938a, topicName=咪达唑仑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f92f32859800, createdName=zhanfl, createdTime=Mon Dec 14 21:26:00 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709014, encodeId=6f731e0901455, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Mon Apr 20 08:26:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378694, encodeId=96263e86949b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:18:12 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468848, encodeId=c6a41468848cf, content=<a href='/topic/show?id=5e0b49e1106' target=_blank style='color:#2F92EE;'>#异丙酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49711, encryptionId=5e0b49e1106, topicName=异丙酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18a56942427, createdName=lq0303, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516380, encodeId=c5cd1516380f4, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610205, encodeId=b7f1161020574, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378603, encodeId=25c33e860303, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Tue Jan 28 22:50:25 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
    2020-01-30 1478fa69m73暂无昵称

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1944145, encodeId=a6ed194414515, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri Jun 05 03:26:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720575, encodeId=24471e2057557, content=<a href='/topic/show?id=2b3939e938a' target=_blank style='color:#2F92EE;'>#咪达唑仑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39793, encryptionId=2b3939e938a, topicName=咪达唑仑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f92f32859800, createdName=zhanfl, createdTime=Mon Dec 14 21:26:00 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709014, encodeId=6f731e0901455, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Mon Apr 20 08:26:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378694, encodeId=96263e86949b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:18:12 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468848, encodeId=c6a41468848cf, content=<a href='/topic/show?id=5e0b49e1106' target=_blank style='color:#2F92EE;'>#异丙酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49711, encryptionId=5e0b49e1106, topicName=异丙酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18a56942427, createdName=lq0303, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516380, encodeId=c5cd1516380f4, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610205, encodeId=b7f1161020574, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378603, encodeId=25c33e860303, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Tue Jan 28 22:50:25 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
    2020-01-30 lq0303
  6. [GetPortalCommentsPageByObjectIdResponse(id=1944145, encodeId=a6ed194414515, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri Jun 05 03:26:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720575, encodeId=24471e2057557, content=<a href='/topic/show?id=2b3939e938a' target=_blank style='color:#2F92EE;'>#咪达唑仑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39793, encryptionId=2b3939e938a, topicName=咪达唑仑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f92f32859800, createdName=zhanfl, createdTime=Mon Dec 14 21:26:00 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709014, encodeId=6f731e0901455, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Mon Apr 20 08:26:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378694, encodeId=96263e86949b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:18:12 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468848, encodeId=c6a41468848cf, content=<a href='/topic/show?id=5e0b49e1106' target=_blank style='color:#2F92EE;'>#异丙酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49711, encryptionId=5e0b49e1106, topicName=异丙酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18a56942427, createdName=lq0303, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516380, encodeId=c5cd1516380f4, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610205, encodeId=b7f1161020574, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378603, encodeId=25c33e860303, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Tue Jan 28 22:50:25 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1944145, encodeId=a6ed194414515, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri Jun 05 03:26:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720575, encodeId=24471e2057557, content=<a href='/topic/show?id=2b3939e938a' target=_blank style='color:#2F92EE;'>#咪达唑仑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39793, encryptionId=2b3939e938a, topicName=咪达唑仑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f92f32859800, createdName=zhanfl, createdTime=Mon Dec 14 21:26:00 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709014, encodeId=6f731e0901455, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Mon Apr 20 08:26:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378694, encodeId=96263e86949b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:18:12 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468848, encodeId=c6a41468848cf, content=<a href='/topic/show?id=5e0b49e1106' target=_blank style='color:#2F92EE;'>#异丙酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49711, encryptionId=5e0b49e1106, topicName=异丙酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18a56942427, createdName=lq0303, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516380, encodeId=c5cd1516380f4, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610205, encodeId=b7f1161020574, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378603, encodeId=25c33e860303, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Tue Jan 28 22:50:25 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1944145, encodeId=a6ed194414515, content=<a href='/topic/show?id=55063866061' target=_blank style='color:#2F92EE;'>#右美托咪啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38660, encryptionId=55063866061, topicName=右美托咪啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri Jun 05 03:26:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720575, encodeId=24471e2057557, content=<a href='/topic/show?id=2b3939e938a' target=_blank style='color:#2F92EE;'>#咪达唑仑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39793, encryptionId=2b3939e938a, topicName=咪达唑仑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f92f32859800, createdName=zhanfl, createdTime=Mon Dec 14 21:26:00 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709014, encodeId=6f731e0901455, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Mon Apr 20 08:26:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378694, encodeId=96263e86949b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:18:12 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468848, encodeId=c6a41468848cf, content=<a href='/topic/show?id=5e0b49e1106' target=_blank style='color:#2F92EE;'>#异丙酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49711, encryptionId=5e0b49e1106, topicName=异丙酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18a56942427, createdName=lq0303, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516380, encodeId=c5cd1516380f4, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610205, encodeId=b7f1161020574, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 30 10:26:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378603, encodeId=25c33e860303, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Tue Jan 28 22:50:25 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
    2020-01-28 qingfengqishi5

    学习了,学习了

    0

相关资讯

Eur Rev Med Pharmacol Sci:异丙酚或七氟醚麻醉对肺癌切除术患者围术期炎症反

与七氟醚麻醉相比,异丙酚麻醉可显著降低肺癌切除术患者围术期炎症反应,缩短术后恢复时间,保护患者肺功能,改善术后认知功能,降低术中不良反应发生率。

Medicine:术前催眠会话对双异丙酚需求量的影响

自动化管理丙泊酚可用于客观评估催眠疗法的非药物麻醉作用。本研究旨在评估催眠会话对麻醉诱导中丙泊酚的用量的影响。 采用随机、常规护理控制、单中心、患者单盲试验研究设计,在法国三级护理中心进行,时间为2012年11月至2013年12月,纳入了全身麻醉下接受外科手术的成年患者。 术前使用计算机生成的随机列表将患者随机分组,分为术前对话催眠会话组或常规护理组。由专业治疗师在安静的环境中进行会话

Adv Clin Exp Med:地氟醚和异丙酚预处理对心肌缺血再灌注损伤的影响

背景与目的:预处理是预防冠状动脉旁路移植术中发生心肌缺血性损伤的最有效机制之一。我们的目的是研究不同浓度的异丙酚和/或地氟醚给药方案在预防心肌缺血再灌注损伤方面的影响。

Crit care med:异丙酚对人骨骼肌细胞生物能的影响!

异丙酚可能对线粒体功能产生不利影响,异丙酚输注综合征的临床特征提示这可能与丙泊酚相关的生物能量衰竭有关。近期,一项发表在杂志Crit care med上的研究旨在评估异丙酚治疗浓度对人骨骼肌细胞能量代谢的影响。此项研究是对人骨骼肌细胞的体外研究。受试人群为接受髋关节手术的患者和健康的志愿者。研究者们进行股外侧肌活检以获得培养的肌管,后将其暴露于1-10μg/mL范围的异丙酚96小时。细胞外通量分析

无抽搐电休克治疗使用异丙酚静脉麻醉致严重过敏一例报道

王某42体重60kg王某因抑郁症一年入院,药物治疗效果不明显,拟行无抽搐电休克治疗。(ECT治疗是在麻醉状态下给与病人短暂适量的电流对大脑进行刺激,引起病人意识丧失,皮层广泛性脑电发放和全身性抽搐发作,以达到控制精神症状的一种治疗方法。

.Interact Cardiovasc Thorac Surg:在右室缺血再灌注中七氟醚比异丙酚提供更好的血流动力学稳定性

评价在急性右心室缺血再灌注中七氟醚是否比异丙酚具有更好的血流动力学稳定性。